

Application No. 09/914,708


Reply to Office Action

## AMENDMENTS TO THE CLAIMS

RECEIVED  
CENTRAL FAX CENTER  
JUL 18 2006

This listing of claims replaces all prior versions and listings of claims in the application.

1. (Currently Amended) A method of treating ~~an intra-organellar acidification of intracellular organelles~~ a condition treatable by the inhibition of vacuolar-type (H<sup>+</sup>)-ATPase, said method comprising administering to a patient an amount effective to ~~treat intra-organellar acidification of intracellular organelles of a~~ inhibit vacuolar-type (H<sup>+</sup>)-ATPase of at least one compound of the formula:



(I).

wherein R<sup>1</sup> and R<sup>2</sup> are the same or different and each is H, a straight-chain or branched saturated or unsaturated alkyl, an aryl, R<sup>6</sup>CH<sub>2</sub>-, R<sup>6</sup>CO-, or R<sup>6</sup>SO<sub>2</sub>-, wherein R<sup>6</sup> is H, a straight-chain or branched saturated or unsaturated alkyl, or an aryl; R<sup>3</sup> is H, a straight-chain or branched saturated or unsaturated alkyl, an aryl, an oxime, or an oxime methyl ether; the aromatic ring is unsubstituted or substituted with at least one substituent selected from the group consisting of a halogen, a nitro, an amino, a hydroxyl, a thio, an acyl, an alkyl, and a cyano; the saturated alkyl, unsaturated alkyl and aryl substituents defined in R<sup>1</sup>-R<sup>3</sup> and R<sup>6</sup> are unsubstituted or substituted with at least one substituent selected from the group consisting of a halogen, a nitro, an amino, a hydroxyl, a thio, an acyl, an alkyl, and a cyano; and Z is a contiguous linker comprising a chain of 7-10 atoms which, together with the five atoms beginning with the carbon of the aromatic ring of formula (I) in meta-relationship with OR<sup>1</sup> and ending with the carbon directly attached to the alkyl oxygen of the lactone of formula (I), said carbons being covalently bonded to either end of linker Z, integrally form a 12-15 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof, wherein the condition is selected from the group consisting of urinary acidification, bone resorption, osteoporosis, fertility, angiogenesis, glaucoma, and Alzheimer's disease.